Amylin, amide, rat acetate is a potent and high affinity ligand of AMY1 and AMY3 receptors and variably of AMY2 receptors.

Amylin, amide, human is a 37-amino acid peptide hormone co-secreted with insulin to regulate postprandial glucose levels, reducing glucagon secretion and delays gastric emptying. DAP Amide's tendency to aggregate into amyloid fibrils is associated with pancreatic β-cell damage in type 2 diabetes.

Amylin (1-37), human acetate (hIAPP (1-37), acetate), a peptide hormone containing 37 amino acids secreted by the pancreas in conjunction with insulin, inhibits glucagon secretion and produces satiety during glucose homeostasis, and is a major component of amyloid deposits in the pancreas of patients with type 2 diabetes.

Eloralintide (LY 3841136) sodium is an AMYR agonist that shows promise for research in type 2 diabetes and obesity.

Amylin is a peptide that displays 50% homology with calcitonin gene-related peptide (CGRP), Amylin is colocalized with somatostatin in endocrine cells of the gastric fundus. In isolated mouse stomach, amylin caused a concentration-dependent decrease in ac

Pramlintide acetate, a polypeptide analogue of human amylin, functions as an antidiabetic agent and exhibits antineoplastic activity in colorectal cancer.

AC 187 Acetate is a potent antagonist of amylin receptor .AC 187 shows more selective for amylin receptor than calcitonin and CGRP receptors.

cAC 253 acetate (TP2135 Free base) is an amylin antagonist. cAC 253 acetate inhibits 125I-adrenomedullin binding, with an IC50 of 25 nM.

Lenbelintide is a dual amylin/calcitonin receptor agonist, useful in studies related to obesity.

Amylin (IAPP), feline is the peptide subunit of amyloid found in pancreatic islets of type 2 diabetic patients and in insulinomas.

Davalintide is an Amylin-mimetic peptide known for its high potency and extended action. It is a highly effective agonist of the amylin receptor (IC50 = 0.04 nM), calcitonin receptor (IC50 = 0.06 nM), and calcitonin gene-related peptide receptor [CGRP receptor] (IC50 = 3.1 nM). Davalintide demonstrates greater efficacy than Amylin in cyclic adenosine monophosphate production through calcitonin receptor activation (EC50 = 1.4 nM). It modulates blood glucose and body weight through mechanisms such as delaying gastric emptying, inhibiting glucagon secretion, and reducing food intake. Davalintide is utilized in research related to anti-obesity and antidiabetic treatments.

Cagrilintide is a long-acting amylin analogue acting as a dual agonist of the amylin receptor and calcitonin receptor, reducing body weight and food intake for obesity research.

CTR/AMYR agonist-1 is a CTR/AMYR agonist with an EC50 range of 0.56-6.9 nM. It is applicable in metabolic disease research.

KBP-066A is a long-acting dual agonist of amylin and calcitonin receptor. It strongly activates CTR and AMY-R without off-target activity. In diabetic rat models, KBP-066A reduces fasting blood glucose, fasting insulin levels, and body weight. It is useful in the study of type 2 diabetes and obesity.

Batelintide is a dual amylin/calcitonin receptor (amylin/calcitonin receptor) agonist with antidiabetic properties.

BGM1812 is a dual agonist that simultaneously activates the amylin receptor (hAMY3R) with an EC50 of 0.627 nM and the calcitonin gene-related peptide receptor (hCTR) with an EC50 of 2.27 nM. BGM1812 promotes weight loss in diet-induced obesity (DIO) rats, increases lean body mass, and reduces fat mass. It is suitable for obesity-related research.

KBP-089 is a dual agonist for both amylin (Amylin) and calcitonin receptor (CalcitoninReceptor). It contributes to weight reduction, reduced adipose tissue, and improved glucose tolerance in obese rats. KBP-089 also facilitates the clearance of lipid accumulation in the liver and muscles, enhancing glucose homeostasis and insulin sensitivity. This compound is applicable for research in obesity and type 2 diabetes.

San45 is a non-selective dual agonist of amylin and calcitonin receptors (DACRA), exhibiting non-selective efficacy for the calcitonin receptor (CTR) and amylin receptor 1 (AMY₁R). It serves as a stabilizer of receptor-ligand complexes and a prolonged activator of the cAMP signaling pathway. With conjugated lipid modifications, San45 is utilized in obesity-related research.

NN1213 (Peptide 21) is a long-acting human amylin peptide analogue that functions as a selective amylin receptor agonist. It has an EC50 of 0.177 nM for hAMY3R and 0.262 nM for rAMY3R. In both rat and dog models, NN1213 significantly reduces appetite and is utilized in anti-obesity research.

Petrelintide (ZP8396) acetate is an amylin analog with potential for weight reduction, suitable for diabetes research.

Pramlintide, a polypeptide analog of human amylin, is an antidiabetic agent with antineoplastic properties in colorectal cancer.

Colulintide is an analog of amylin, utilized in obesity research.

Amylin (8-37), rat, a truncated analog of native Amylin, selectively inhibits insulin-related glucose uptake and glycogen deposition in muscle tissue. Amylin, also known as islet amyloid precursor peptide (IAPP), is co-secreted with insulin from pancreatic β-cells.

CTR/AMYR modulator-2 (Example 107) is an agonist of the amylin receptor 3 (bAMY3R) with an EC50 value of less than 500 nM for stimulating intracellular cAMP production. It also acts as an agonist for the calcitonin receptor (bCTR) with an EC50 value of less than 5000 nM. CTR/AMYR modulator-2 is applicable in research on type 2 diabetes and obesity.